Resveratrol, a natural polyphenol with antioxidant, anti-inflammatory and neuroprotective properties, has limited clinical applications due to its poor aqueous solubility and low bioavailability through conventional administration routes. The current work aimed to develop and evaluate resveratrol-loaded nanostructured lipid carriers (RS-NLCs) to improve resveratrol's ocular delivery. RS-NLCs were manufactured by melt emulsification and ultrasonication, optimized for particle size (104.47 ± 13.32 nm), polydispersity index (0.394 ± 0.070), and high entrapment efficiency (85.88 ± 0.32%). In vitro release studies demonstrated an initial burst release followed by sustained release of resveratrol from RS-NLCs over 24 hours. Transmission electron microscopy revealed smooth, spherical RS-NLC morphology with a size of 205.88 nm. Ex vivo trans-corneal permeation investigation using isolated goat corneas showed significantly higher resveratrol flux (4.03 ± 0.20 μg/cm2/h) and permeability coefficient (40.37 ± 2.02 x 10-4 cm/h) for RS-NLCs compared to resveratrol suspension. The nanostructured lipid formulation enhanced resveratrol's corneal penetration by 11 folds, suggesting RS-NLCs as a promising carrier for improved ocular delivery of resveratrol and treatment of ocular diseases associated with oxidative stress and inflammation.